Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,044.67 -13.51 (-1.28%)

Official Closing Price Updated: 7:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗

Today 14:50 EST

These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue.

Via The Motley Fool

Topics Intellectual Property

Over 60% of Eli Lilly's Revenue Comes From Its GLP-1 Drugs. Should Investors Be Worried? ↗

Today 11:50 EST

Mounjaro and Zepbound generated a combined $11.7 billion in sales for the company in its most recent quarter.

Via The Motley Fool

The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash

Today 11:35 EST

The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to...

Via MarketMinute

Topics Intellectual Property Lawsuit

FDA "Swift Action" Warning Sends Hims & Hers into a Tailspin ↗

Today 4:30 EST

Via Chartmill

Why Eli Lilly Stock Just Popped ↗

Today 11:05 EST

Novo Nordisk just did Eli Lilly stock a huge favor.

Via The Motley Fool

Topics Lawsuit

Grounded in Reality or Echoes of '99? Merrill Strategists Say Today’s S&P 500 Is a Different Beast

Today 10:42 EST

As the S&P 500 (INDEXSP: .INX) pushes toward the 7,100 mark in early 2026, a growing chorus of investors is nervously glancing back at the ghosts of 1999. With the index having notched double-digit...

Via MarketMinute

Topics Artificial Intelligence Lawsuit Stocks

The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn

Today 10:19 EST

The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of...

Via MarketMinute

Topics Earnings Intellectual Property

The GLP-1 Reckoning: Why Hims & Hers (HIMS) Pivoted and Shed 20% of Its Value

Today 9:36 EST

On February 9, 2026, the telehealth landscape faces a reckoning. Hims & Hers Health (NYSE: HIMS), a company that once seemed invincible during the weight-loss drug gold rush of 2025, is currently...

Via Finterra

Topics Earnings Economy Intellectual Property

Eli Lilly Bets $2.4 Billion On Small Biotech To Boost Future Cell Treatments ↗

Today 9:11 EST

Eli Lilly shares rise after announcing a $2.4 billion deal to buy Orna Therapeutics, strengthening its push into genetic medicine despite mixed markets.

Via Benzinga

Monday's pre-market session: top gainers and losers in the S&P500 index ↗

Today 8:35 EST

Via Chartmill

LLY Stock Climbs Pre-Market On $2.4 Deal To Acquire Orna Therapeutics ↗

Today 7:17 EST

The acquisition will strengthen Lilly’s pipeline with a new class of therapies built on engineered circular RNA and proprietary lipid nanoparticles.

Via Stocktwits

Dow 50,000: A Milestone for the History Books Amidst an AI Spending War ↗

Today 2:36 EST

Via Chartmill

Topics Artificial Intelligence Stocks

HIMS Stock In Turmoil: Retail Bulls Bet On Rebound, Skeptics See Bloodbath After Compounded Weight-Loss Pill Halt ↗

February 08, 2026

Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight.

Via Stocktwits

Topics Intellectual Property Law Enforcement

Eli Lilly Shares Surge on Weight-Loss Drug Momentum. Is It Time to Buy the Stock? ↗

February 08, 2026

It doesn't look too late to buy the stock.

Via The Motley Fool

Medicare Changes in 2026 Every Retiree Needs to Know: The Good, the Bad, and the Ugly ↗

February 08, 2026

Retirees should brace themselves for both positive and negative changes to Medicare this year.

Via The Motley Fool

Topics Economy Government Retirement

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 07, 2026

Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.

Via The Motley Fool

3 Things Investors Need to Know About the Healthcare Sector in 2026 ↗

February 07, 2026

The most recent gold rush in weight loss drugs isn't done just yet.

Via The Motley Fool

Topics Economy

1 Brilliant Vanguard Index Fund to Buy Before It Soars 120%, According to a Wall Street Analyst ↗

February 07, 2026

Tom Lee says the S&P 500 (a benchmark for the U.S. stock market) can hit 15,000 by 2030.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut ↗

February 06, 2026

Via MarketBeat

Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition

February 06, 2026

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...

Via MarketMinute

Topics Earnings Economy

AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months

February 06, 2026

In a breakthrough that many are calling the "Penicillin Moment" of the 21st century, researchers at the Massachusetts Institute of Technology, led by bioengineering pioneer James Collins, have...

Via TokenRing AI

Topics Artificial Intelligence

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

February 06, 2026

Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,...

Via MarketMinute

Topics Intellectual Property

Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn't Ignore ↗

February 06, 2026

The market for obesity drugs may soon reach almost $100 billion.

Via The Motley Fool

The $49 Disruptor: Hims & Hers Ignites a Brutal Price War in the Weight-Loss Drug Market

February 06, 2026

The long-standing duopoly of the weight-loss drug market faced its most significant challenge yet this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a breakthrough $49 compounded oral...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

What Does the Market Think About Eli Lilly and Co? ↗

February 06, 2026

Via Benzinga

Why Shares of Novo Nordisk Stock Collapsed This Week ↗

February 06, 2026

The drugmaker is facing pricing pressures on its weight loss medications.

Via The Motley Fool

The Trillion-Dollar Divergence: Eli Lilly Hits Milestone While Novo Nordisk Faces 'Supply Chain Reset'

February 06, 2026

The global race for obesity market dominance reached a historic turning point this week as Eli Lilly and Company (NYSE: LLY) officially crossed the $1 trillion market capitalization threshold,...

Via MarketMinute

Topics Economy

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance

February 06, 2026

As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade...

Via Finterra

Topics Economy Government Intellectual Property

Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse

February 06, 2026

As of February 6, 2026, Biogen Inc. (NASDAQ: BIIB) stands at a critical crossroads in its nearly 50-year history. Once the undisputed titan of the Multiple Sclerosis (MS) market, the Cambridge-based...

Via Finterra

Topics Earnings Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.